Quell Therapeutics named a “Fierce 15“ Company by FierceBiotech

Quell Therapeutics, a biotechnology company focused on developing engineered T regulatory (Treg) cell therapies, announces that it has been named by FierceBiotech as one of 2019’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.


“We are thrilled to be named among the industry’s most exciting new biotech companies. At Quell we are taking a leadership position in the pioneering new field of Genetically Modified Regulatory T Cell therapies (modified Tregs), with the potential of modified Treg therapies to address conditions of immune dysfunction holding great promise for our patients,” said Iain McGill, Chief Executive Officer of Quell Therapeutics. “The talented and growing team at Quell is making rapid strides in developing our platform and building a pipeline of products to address a range of conditions including solid organ transplant rejection, autoimmune and inflammatory diseases. It is a tremendous honour that our approach and our team have been recognized with this Fierce 15 award.”


“This year has seen unrivalled scientific talent in the early-stage life sciences world, and it has been a pleasure to for us at FierceBiotech to speak to all 15 winners and hear their passion, progress and panache,” said Ben Adams, Senior Editor of FierceBiotech. “Each company brought something different, exciting and potentially life-changing for myriad patients around the world across a host of diseases and disorders, using cutting-edge science, top-notch teams and a drive to genuinely make the world a better place, despite the risks and challenges that, as ever in biotech, lay ahead.”

Back to News and insights